Oticon Medical expands non-surgical bone conduction options: full analysis
Oticon Medical is expanding its non-surgical bone conduction lineup with the launch of Ponto Instant, a portfolio that introduces Instant HearBand and Instant SoundConnector as new wearable options for Ponto sound processors. In launch materials, the company positioned the products as a way to widen access to bone conduction hearing for both children and adults who want a non-surgical solution, either as a longer-term choice or as a step before implantation. (pressreleasehub.pa.media)
The move fits with Oticon Medical’s broader push to offer more choice across bone conduction hearing. In July 2024, the company announced U.S. FDA clearance and CE marking for its Sentio system, its first active transcutaneous bone conduction platform, and described that launch as part of a “complete portfolio” strategy. Oticon Medical has repeatedly framed that approach around “freedom of choice,” meaning patients and clinicians can match technology to anatomy, age, preferences, and reimbursement realities rather than steering everyone toward a single pathway. (oticonmedical.com)
Ponto Instant appears to build on that same logic. According to the launch announcement, the portfolio now includes Softband 5, plus the new Instant HearBand, described as a discreet behind-the-head wearable alternative, and Instant SoundConnector, a small accessory that can be fitted to a cap or other headwear. Oticon Medical’s existing materials already describe non-surgical Ponto wear as useful for children who need early auditory access, adults who don’t benefit from conventional hearing aids, and people with temporary ear problems or those evaluating bone conduction before surgery. (pressreleasehub.pa.media)
There’s also a business backdrop here. On March 31, 2026, Demant completed the sale of Oticon Medical to Impilo, and Oticon Medical said the transaction would preserve operational continuity while supporting future development, including the Ponto 6 family and Sentio 2. That matters because some audiology discussions over the past two years have reflected uncertainty about long-term roadmap and service continuity after earlier strategic changes. The new Ponto Instant launch gives the company a concrete product signal that it intends to keep investing in the category. (oticon.de)
Independent clinical background supports the relevance of the non-surgical segment. Johns Hopkins Medicine notes that bone conduction hearing systems now include both surgical and non-surgical options, and that non-surgical devices are typically worn on a headband or attached to the skin, often as part of evaluation and candidacy assessment. Oticon Medical’s own patient-facing materials similarly describe trying Ponto on a softband or headband before proceeding with implantation. In other words, this isn’t a fringe use case, it’s a standard part of how many patients enter the bone conduction pathway. (hopkinsmedicine.org)
Why it matters: For veterinary professionals, this is primarily a medical-device market signal rather than a practice-changing animal health development. Still, it’s a useful one. Across human and veterinary care, companies are trying to reduce friction around adoption by offering less invasive entry points, more flexible wearability, and easier trial experiences. Ponto Instant reflects that same pattern: meet people earlier, lower the commitment threshold, and create a bridge from evaluation to longer-term therapy when appropriate. For clinicians and practice leaders tracking medtech trends, that’s a familiar commercialization playbook, and one that often translates into stronger uptake when the technology solves a real access or comfort problem. (pressreleasehub.pa.media)
Another practical takeaway is that form factor still matters. A behind-the-head band and a connector that can attach to existing headwear may sound incremental, but comfort, discretion, and day-to-day usability often determine whether a patient actually sticks with a device. That’s especially relevant in pediatric settings, trial periods, and any situation where a pet parent, caregiver, or patient is weighing whether to move forward with a more permanent intervention. This is an inference based on the product design emphasis and the established role of non-surgical trials, rather than a claim backed by published outcomes data for these new accessories specifically. (pressreleasehub.pa.media)
What to watch: The next key questions are whether Oticon Medical publishes more clinical or usability data on the new wearables, how quickly Ponto Instant rolls out across major markets, and whether the company pairs this launch with the next-generation Ponto 6 roadmap it referenced after the Impilo transaction. (oticon.de)